Generate Biomedicines: Post Mega-Money IPO, Caution Is Warranted
Generate Biomedicines Inc GENB
$14.00
▼ -0.21%
($-0.03)
📅 Earnings This Week
Open
$13.77
Prev Close
$14.03
Day Range
$13.46 – $14.10
52W Range
$11.00 – $18.18
Market Cap
$1.79B
Beta
0.54
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-02-27 |
| Shares Out. | 128,190,000 |
| Website | generatebiomedicines.com ↗ |
| Phone | 13026587581 |
| Revenue | $7.2M |
| Gross Profit | $7.2M |
| Net Income | -$61.7M |
| Total Assets | $625.7M |
| Total Liabilities | $110.9M |
| Equity | $514.8M |
About Generate Biomedicines Inc
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
Generate Biomedicines Inc is a publicly traded company under the ticker symbol GENB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)